Version Changes
Revised. Amendments from Version 1
We added two short sections which explain: 1. The way in which our hypothesis could be tested, by assessing the direct toxicity of signaling chemicals. 2. The rationale behind not emphasizing the phylogeny when considering the selection of neurotransmitters. Both additions were made in response to the reviewers' comments.
Abstract
In the CNS, minor changes in the concentration of neurotransmitters such as glutamate or dopamine can lead to neurodegenerative diseases. We present an evolutionary perspective on the function of neurotransmitter toxicity in the CNS. We hypothesize that neurotransmitters are selected because of their toxicity, which serves as a test of neuron quality and facilitates the selection of neuronal pathways. This perspective may offer additional explanations for the reduction of neurotransmitter concentration in the CNS with age, and suggest an additional role for the blood-brain barrier. It may also suggest a connection between the specific toxicity of the neurotransmitters released in a specific region of the CNS, and elucidate their role as chemicals that are optimal for testing the quality of cells in that region.
Introduction
Some non-peptide chemicals that function as neurotransmitters in the central nervous system (CNS), such as dopamine and serotonin, have toxic effects 1– 4. Neurodegeneration can result from the deregulation of the concentration of these neurotransmitters 5– 7. It is known that neurotransmitters such as serotonin, acetylcholine (ACh), glutamate and gamma-aminobutyric acid (GABA) function as signals between non neuronal cells in the periphery 8– 12, and have evolutionarily conserved roles, serving also as signals in plants 13, 14 and unicellular organisms 15. This does not necessarily explain their adaptive role as signals in the CNS, as at synapses a variety of less toxic chemicals could have served the same role, had they been loaded into vesicles in the pre-synaptic neuron and had complementary receptors on the post-synaptic neuron. In the following we attempt to highlight the potential insights that may arise from applying the theory of signal selection 16 to the evolution of signals between cells in multicellular organisms. The theory of signal selection, based on the handicap principle, suggests that the properties of the signal serve as a test of the information encoded in the signal. The theory revolutionized the study of signaling between organisms 17, 18. The application of the theory to the evolution of neurotransmitters suggests that neurotransmitters are selected in part because of their toxicity, which serves as a test of the quality of the releasing cell and its connectivity with neighboring cells, and facilitates the selection of neuronal pathways.
The theory of signal selection
The theory of signal selection was developed by Zahavi 19, 20 to explain why peahens are stimulated by a trait that imposes a handicap on the male, rather than paying attention to more positive traits in the males that court them. Zahavi suggested that peahens are attracted by peacocks that carry the burden of a long and heavy tail because this burden constitutes a handicap that tests the quality of the displaying peacock. This interpretation pointed at the objective information provided by the signal, which results in the peahen responding to one peacock and rejecting others; it is not coincidental that peahens are attracted to males with heavy tails, rather, it is the tested and reliable information provided by the cumbersome tail that selected for the interest of the female in the level of the handicap imposed on the male by its tail.
We suggest that, similarly to the burden imposed by the peacock’s tail, a signal’s toxicity is necessary to impose a specific chemical burden on the signaling cell to ensure that the signal inherently provides reliable information on some properties of the signaling cell. It is reasonable to assume that if signals within multicellular organisms were consensus signals that did not inherently correlate to a specific metabolic activity of the signaling cell, a larger variety of chemicals could have been selected as signals within multicellular organisms. In addition, phenotypes which had not developed to signal could signal in error, while the level of the signal could misrepresent the metabolic state of the signaler. We suggest that the investment in reliable signaling in multicellular organisms is necessary in order to reduce the potential harm of such errors 16. Tests must be difficult in order to provide meaningful and reliable results 16, and hence we expect that, if neurotransmitters also test the quality of the releasing cell, they should be directly toxic in a way that tests the message encoded in the signal.
Neurotransmitter toxicity and its implication in neurodegeneration
In the CNS, neurotransmitters play a central role in relaying information at chemical synapses. This role involves their vesicular secretion by the pre-synaptic cell and interaction with receptors on the post-synaptic cell. However, neurotransmitters are also released outside synapses in high concentrations prior to blood-brain barrier development 21, 22 and as part of non-synaptic forms of intercellular communication in the mature brain 23. Synaptic transmission requires the rapid clearance of the secreted or released neurotransmitter via uptake by neurons and astrocytes 24. When these mechanisms are deregulated, the accumulation of neurotransmitter in the extracellular matrix can lead to neurodegeneration 5– 7. Here we review briefly the toxicity of some neurotransmitters and its role in neurodegeneration.
Glutamate
Glutamate exerts neurotoxicity via excitotoxicity caused by the overactivation of NMDA receptors 25 and oxidative toxicity caused by the inhibition of cysteine uptake via uptake by the cysteine-glutamate anti-porter 26. As glutamate uptake is an energy-dependent process that involves the co-transport of sodium 27, glutamate uptake is reversed in hypoxic conditions and leads to an increase in extracellular glutamate 28. The increase of extracellular glutamate has been implicated as a causative factor in numerous pathologies, including stroke 29, Huntington’s disease, Parkinson’s disease and amyotrophic lateral sclerosis 30.
Despite its abundance, glutamate is stored mostly in subcellular compartments 31: in astrocytes its uptake is coupled with its conversion to glutamine 32 and in neurons the synthesis of glutamate from 2-oxoglutarate 33 or glutamine 32 is correlated to its uptake into vesicles, suggesting that it is also potentially toxic within the cytoplasm. In addition to glutamate toxicity that is mediated by its interaction with receptors and secondary to its uptake mechanisms, evidence of the interaction of glutamate with oxygen radicals could point to potential direct damage of glutamate to membranes. In the presence of hydroxyl radicals and molecular oxygen, glutamate is oxidized to 2-oxoglutarate in a reaction that releases hydrogen peroxide 34, 35. Glutamate in particular has a relatively high yield of peroxide in the presence of oxygen radicals, relative to glutamine, glycine and aspartate 34. This process is also iron-dependent, the presence of which is a causative factor of neurodegeneration involving radical oxygen species 36.
Dopamine
Dopamine is involved in the pathogenesis of Parkinson’s disease, which involves the degeneration of dopaminergic neurons in the substantia nigra, leading to motor dysfunction 5, 6. The loss of dopaminergic neurons has been linked to dopamine’s cytotoxicity that results from the deregulation of its metabolism in these neurons 6.
Dopamine is directly toxic in its oxidized semiquinone and quinone forms 1, 37. Dopamine toxicity is also related to the presence of metal ions such as iron 4, which increase its oxidation to neurotoxic metabolites 38, while metal ion chelators have a protective effect in Parkinson’s disease 39. It has already been suggested that redox mechanisms that render intracellular dopamine toxic in the cytosol could also render extracellular dopamine toxic 3.
Serotonin
Serotonin is sensitive to oxygen radicals, and its indole moiety is readily oxidized in the presence of hydroxyl radicals to form neurotoxic metabolites of serotonin 1. The indole moiety of serotonin can undergo oxidation by indoleamine 2,3-dioxygenase to form kynurenine, which can be metabolized further into various neurotoxic chemicals 40. This pathway of serotonin metabolism has been implicated in neurodegeneration associated with depression 41. Serotonin is toxic in the presence of copper 42, causing intracellular damage such as DNA strand cleavage 43. Serotonin is also toxic in the presence of iron 2, causing mitochondrial damage 44. This suggests a role for serotonin in copper and iron mediated neurodegeneration.
Serotonin can also interact with lipid membranes 45, partially intercalating into the phospholipid layer and thus causing structural changes in the membrane. It has been shown that the interaction of neurotransmitters with the cell membrane can have a non-specific anesthetic effect on receptor activity 46, and so chronic exposure to serotonin may alter membranal homeostasis.
Acetylcholine
As far as we are aware, there is currently no experimental evidence of direct ACh toxicity. However, the overstimulation of ACh receptors as a result of ACh accumulation that is caused by acetylcholinesterase inhibition can lead to cholinergic toxicity 47, 48. This toxicity may involve the release of choline from phosphatidylcholine that is downstream of muscarinic ACh receptors 49, leading to phosphatidylcholine depletion. In addition, the use of nicotinic ACh receptor antagonists has shown to reduce the neurotoxicity of the Alzheimer’s disease-related peptide, β-amyloid 50.
ACh interacts with lipid bilayers and elicits changes in the organization of the lipid bilayer 51. This interaction is non-specific, slower than receptor activation, and has a longer duration 46. We speculate that the accumulation of ACh could interfere with the membrane morphology 46 and consequently may interfere with its function.
Testing neurotransmitter toxicity
Though the putative toxicity of neurotransmitters presented above suggests that our hypothesis can be generalized to most neurotransmitters, only a small number of neurotransmitters have been shown to have direct toxicity. In order to test the direct toxicity of a neurotransmitter, it is necessary to create a cell line that does not express adaptive defense mechanisms (such as specific receptors or degrading enzymes that bind the neurotransmitter), and expose it to varying concentrations of the neurotransmitter. If the concentration of the neurotransmitter in the medium has no effect on the viability of the cells, then it is reasonable to assume that the neurotransmitter is not directly toxic. This type of experiment could test our hypothesis.
The function of neurotransmitters in the brain – some considerations resulting from our evolutionary perspective
The consideration of a function for neurotransmitters as a reliable representation of the specific activity of the releasing cell, rather than simply as chemicals that facilitate the transfer of information between neurons, may contribute novel deliberations and interpretations of known phenomena.
The formation of connections between neurons in the vertebrate CNS during embryogenesis and development is a dynamic process in which neurons that do not form synapses are eliminated 52, 53, while neurons forming new synapses survive into adulthood 54, 55. In addition, since neurons have an array of potential connections, a selection process is involved in the development and ongoing activity of neuronal networks 52, 55– 57. Hence, we suggest that the toxic neurotransmitters that are released from neurons in the CNS function as tests of neuronal quality. The toxicity is important for the process of selection that is involved the selection of the optimal pathways for relaying information between and within specialized CNS centers.
A better reflection of quality is obtained when tested in more than one parameter. In the choice of mates, birds display their quality through several signals such as dancing, colors and vocalizations 16. This may be also the reason why more than one neurotransmitter participates in the selection of neuronal connections. Indeed, most synapses depend on more than one neurotransmitter in order to function 58.
Several observations support the notion of the importance of neurotransmitters in the selection of synapses: glutamate signaling in the auditory system is essential for the normal development of inhibitory circuits, in which some synapses are strengthened and others are silenced 57. Glutamate is also important in the maturation of neuronal pathways in the mushroom bodies of Drosophila through non-synaptic mechanisms 59. GABA is similarly involved in the development of neuronal circuits through non-synaptic mechanisms 60.
Brain centers and their specific composition of neurotransmitters
If, as we suggest, released neurotransmitters represent the phenotypic qualities of the releasing cell, the fact that specialized CNS centers release a specific combination of neurotransmitters implies that the neurons in these centers have distinct metabolic activities that relate to the function of the center. For example, in the raphe nuclei, the main source of serotonin in the brain, there is a high extracellular concentration of serotonin, the source of which is a non-synaptic release which is correlated with the activity level of the raphe nuclei 61. We suggest that the release of serotonin was adopted, and still functions as, a paracrine signal between cells in the raphe nuclei that facilitates, by a selection process, a local synchronization of activity.
Neurons within a specialized population of cells vary in their morphology, their proximity to the sources of metabolites or to incoming stimuli from outside the center, and may vary also with many other parameters 62. The specific neurons that are phenotypically more capable to carry out their function are those that react to and process the information received in the center, defining the output of the center. For instance, soma size determines electrophysiological differences between neurons of retinal ganglions, larger neurons having greater excitability 63.
It is reasonable to assume that these phenotypic differences that relate to metabolite capability also determine the level of neurotransmitter released by neurons in the ganglion: less active phenotypes cannot counter the toxic effects of the serotonin released by the more active phenotypes, and consequently lower their metabolism in order to reduce the concentration of serotonin around their outer membrane. Indeed, the release of serotonin in the raphe nuclei is reduced by an increase in its extracellular concentration 61, which, we suggest, is a consequence of reduced activity in neurons that reduce their release. If serotonin was not toxic, the more active phenotypes, which produce and release higher concentrations of serotonin, would not reduce the synthesis of serotonin in less active phenotypes, and serotonin release could not serve as a mechanism of selection.
Furthermore we speculate that if the activity of a specific brain center entails the production of a particular waste product, this waste may serve at synapses as an optimal neurotransmitter to ensure that the information provided by the electrical stimulus originates in a specific center.
Phylogeny and neurotransmitters
Glutamate serves as the primary excitatory neurotransmitter at the insect neuromuscular junction 64, 65, whereas in mammals acetylcholine serves this role. The choice of neurotransmitter could be explained by the fundamental anatomical and physiological difference between mammals and insects: while insects receive oxygen directly to cells via trachea, and thus avoid contact between the extracellular medium and oxygen radicals, mammals receive oxygen through the extracellular medium. In other words, the insect neuromuscular junction is not exposed to oxygen to the same degree as the mammalian neuromuscular junction, therefore, glutamate is not exposed to oxidation and can be used as a neurotransmitter without having the same level of toxicity as in mammals. As a consequence of the ability to explain neurotransmitter choice based on anatomical and physiological differences, we did not place emphasis on the phylogenetic context to explain the usage of a particular neurotransmitter for its function.
The blood-brain barrier
The blood-brain barrier of vertebrates separates the extracellular environment of neurons in the CNS from changes caused in peripheral tissues 66. It has been suggested that the blood-brain barrier facilitates the maintenance of the highly regulated microenvironment of the synapse by preventing neurotransmitters synthesized in the periphery from reaching synapses in the CNS, creating a “cross-talk” between peripheral and neuronal signaling 67. We suggest, in addition, that if neurotransmitters test and therefore represent the metabolic activity of neurons, then any influx of neurotransmitters from the periphery into the CNS could potentially interfere with that function. In other words, the extracellular concentration of neurotransmitters can only reliably reflect the metabolism of neurons if it is isolated from neurotransmitters produced in the periphery. This may constitute an additional adaptive significance for the mechanisms that prevent toxic neurotransmitters from diffusing through the blood-brain barrier.
Reduction of neurotransmitters in the aging brain
Aging is accompanied by changes in neurotransmitter concentrations in the brain, and in a number of regions there is a significant decrease in the concentration of glutamate, dopamine and serotonin 68– 71. It is possible to interpret the depletion of certain neurotransmitters in old age as an adaptive response to the reduced ability of aging cells to counter the toxicity of these neurotransmitters. Under such conditions it is preferable to reduce the severity of the test rather than to forgo the test altogether. Indeed, dopamine synthesis is regulated by the redox state of the cell, and oxidative stress leads to an inhibition of tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine 72, 73. This might explain why restoring the toxicity through an increase in the concentration of certain neurotransmitters, in cells that cannot counter this toxicity, may cause long-term damage, as in the case of l-DOPA treatment for Parkinson’s disease 74, while treatment with anti-oxidants has the potential to restore neurotransmitter concentrations to normal levels 75.
The evolution of chemical signaling in the brain
It has already been suggested by Le-Corronc et al. 76 that the developmental role of neurotransmitters as paracrine signals precedes their role as facilitators of synaptic transmission. Our evolutionary perspective suggests that neurotransmitters that functioned in the periphery as paracrine signals, released directly from the cytoplasm, were initially adopted by the CNS to serve as paracrine signals within specialized CNS centers. The toxicity of the neurotransmitters facilitated the selection of the optimal cells for the particular function of the CNS and coordinated the activity of cells within specific CNS centers. The use of these neurotransmitters at synaptic contacts was later adopted as a signature that identifies the origin of the electrical stimulus arriving at the post synaptic neuron, and prevents other electrical stimuli from interfering with the stimuli from the pre-synaptic neuron.
We hope that further studies of the function of a CNS center in relation to its particular metabolism involved in processing information may lead to a greater understanding of the relationship between the activity of neurons within the center, and the specific composition of the neurotransmitters they release.
An evolutionary model of the stages that selected toxic chemicals as signals
Our evolutionary perspective suggests that toxic waste released into the extracellular environment by the signaling cell, a release that is inherently correlated to the activity of the signaling cell, forces neighboring cells to react to counter the toxicity of the release. Their reaction may provide them with information that can contribute to the coordination of their activity with neighboring cells. Here we explain the model in the context of various examples that were instructive in its development.
Different metabolic activities result in the production of particular waste products. For example, oxidative phosphorylation in mitochondria leads inevitably to the production of reactive oxygen species 77. Another example is the release of ACh, which is correlated to calcium influxes 78: as motor activities require the influx of calcium ion into the cytoplasm 79, and as ACh is also a positive ion, its release is an inevitable result of the influx of calcium ions 78. While other positive ions may be released as a result of the influx of calcium, ACh is quickly hydrolyzed outside the cell 80, as opposed to inorganic ions, and therefore reliably reflects in more detail than other ions the current activity of the releasing cell.
It is also reasonable to assume that the level of the waste released is correlated to the level of the activity of the releasing cell, such as the correlation between carbon dioxide production and the level of respiration 81.
Among the waste products released, some are more toxic and potentially harmful to nearby cells, since waste released within a multicellular organism encounters the outer cell membrane of nearby cells in addition to its potential harm to the signaling cell.
Cells exposed to a toxic chemical must counter the toxicity via (1) producing and releasing anti-oxidants, such as the release of ascorbate to reduce dopamine-mediated oxidative damage 37, (2) degrading the chemical enzymatically, such as acetylcholinesterase 80, or (3) transporting the chemical into the cytoplasm where it can be converted into less harmful chemicals or transported into and stored inside vesicles, as in the case of glutamate and dopamine 5, 24.
The uptake of glutamate or the release of antioxidants which counters the toxicity of dopamine is correlated to their respective concentrations outside the cell. The response to a toxic chemical must be related to its concentration if it is to counter its toxicity. In addition, the toxicity also harms the membrane of the releasing cell, limiting its metabolic activity in order to prevent the cell from increasing the level of release beyond its ability to cope with the toxicity, as evidenced by the inhibition of serotonin secretion and synthesis by extracellular serotonin 61.
Consequently, the activity of a cell to counter the toxicity of chemicals in its extracellular environment can provide it with information on its potential to be active as compared with that of the secreting cells. Such information can serve as a cue to facilitate the coordination of activities with those of the releasing cell, for instance, in the course of the development of osteoblasts that is mediated by glutamate 82, to either differentiate, undergo mitosis or apoptosis. Coordination between neighboring cells is necessary within multicellular organisms, and we suggest that the information provided by the reaction to released toxic waste can facilitate this coordination: for instance, in airway epithelium, which coordinates cilia beating via ACh 7 83, or in developing tissues such as developing osteoblasts, which coordinate development via glutamate signaling 84.
Before the organism benefited from the reaction of neighboring cells to the release of the toxic chemical, mutations that resulted in increased synthesis of the released toxic chemical would have been detrimental. However, once neighboring cells became attentive to changes in the level of the released chemical, the organism could benefit from enzymes that increase the production of the toxic chemical in the releasing cell, which can provide more detailed and accurate information about a change in its metabolism, and facilitate the synchronization of activities between neighboring cells.
This extra investment in increasing the production of a toxic chemical (the handicap), changes the released chemical from a cue into a signal, and provides the basis for a paracrine signaling system 16, 85. We follow Maynard Smith and Harper 18 in defining a signal as a trait that benefits the signaler only if the receiver reacts to it in a way that benefits the signaler.
It is interesting to note that the CNS uses ACh to stimulate peripheral cells, which is the same signal that is used in the periphery in paracrine signaling, rather than evolving a novel neurotransmitter, a process that would require the coevolution of receptors and complementary transduction systems to process the information. It is possible that the release of ACh from myocytes 86, which we suggest is an inevitable result of calcium influx, can serve as a paracrine signal and as a retrograde signal that provides reliable information regarding myocyte contraction to extrasynaptic ACh receptors on the motor neuron 85. It is possible that other neurotransmitters also serve as retrograde signals. For example, glutamate serves as a retrograde signal between cerebellar Purkinje neurons 87.
Acknowledgements
We would like to thank David Gurwitz for his insightful comments on the content and presentation of the manuscript, Daniel Offen, Ari Barzilai and Vidyanand Nanjundiah for their comments during the preparation of the manuscript, and Naomi Paz for stylistic improvements.
Funding Statement
The author(s) declared that no grants were involved in supporting this work.
v2; ref status: indexed
References
- 1.Wrona MZ, Yang Z, Zhang F, et al. : Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. NIDA Res Monogr. 1997;173:146–174. [PubMed] [Google Scholar]
- 2.Wrona MZ, Dryhurst G: Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. Chem Res Toxicol. 1998;11(6):639–650. 10.1021/tx970185w [DOI] [PubMed] [Google Scholar]
- 3.Smythies J: The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox Res. 1999;1(1):27–39. 10.1007/BF03033337 [DOI] [PubMed] [Google Scholar]
- 4.Hare DJ, Lei P, Ayton S, et al. : An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chem Sci. 2014;5:2160–2169 10.1039/C3SC53461H [DOI] [Google Scholar]
- 5.Caudle WM, Richardson JR, Wang MZ, et al. : Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci. 2007;27(30):8138–8148. 10.1523/JNEUROSCI.0319-07.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bisaglia M, Greggio E, Beltramini M, et al. : Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson’s disease therapies. FASEB J. 2013;27(6):2101–2110. 10.1096/fj.12-226852 [DOI] [PubMed] [Google Scholar]
- 7.Paula-Lima AC, Brito-Moreira J, Ferreira ST: Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer’s disease. J Neurochem. 2013;126(2):191–202. 10.1111/jnc.12304 [DOI] [PubMed] [Google Scholar]
- 8.Hayashi M, Yamada H, Uehara S, et al. : Secretory granule-mediated co-secretion of L-glutamate and glucagon triggers glutamatergic signal transmission in islets of Langerhans. J Biol Chem. 2003;278(3):1966–1974. 10.1074/jbc.M206758200 [DOI] [PubMed] [Google Scholar]
- 9.Gammelsaeter R, Frøyland M, Aragón C, et al. : Glycine, GABA and their transporters in pancreatic islets of Langerhans: evidence for a paracrine transmitter interplay. J Cell Sci. 2004;117(Pt 17):3749–3758. 10.1242/jcs.01209 [DOI] [PubMed] [Google Scholar]
- 10.Stunes AK, Reseland JE, Hauso O, et al. : Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes Obes Metab. 2011;13(6):551–558. 10.1111/j.1463-1326.2011.01378.x [DOI] [PubMed] [Google Scholar]
- 11.Watanabe H, Rose MT, Aso H: Role of peripheral serotonin in glucose and lipid metabolism. Curr Opin Lipidol. 2011;22(3):186–191. 10.1097/MOL.0b013e3283462273 [DOI] [PubMed] [Google Scholar]
- 12.Wessler I, Kirkpatrick CJ: Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008;154(8):1558–1571. 10.1038/bjp.2008.185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bouché N, Lacombe B, Fromm H: GABA signaling: a conserved and ubiquitous mechanism. Trends Cell Biol. 2003;13(12):607–610. 10.1016/j.tcb.2003.10.001 [DOI] [PubMed] [Google Scholar]
- 14.Forde BG, Lea PJ: Glutamate in plants: metabolism, regulation, and signalling. J Exp Bot. 2007;58(9):2339–2358. 10.1093/jxb/erm121 [DOI] [PubMed] [Google Scholar]
- 15.Csaba G: The hormonal system of the unicellular Tetrahymena: a review with evolutionary aspects. Acta Microbiol Immunol Hung. 2012;59(2):131–156. 10.1556/AMicr.59.2012.2.1 [DOI] [PubMed] [Google Scholar]
- 16.Zahavi A, Zahavi A: The Logic of Analog Signaling and the Theory of Signal Selection. Isr J Ecol Evol. 2012;58:269–278. [Google Scholar]
- 17.Grafen A: Biological signals as handicaps. J Theor Biol. 1990;144(4):517–546. 10.1016/S0022-5193(05)80088-8 [DOI] [PubMed] [Google Scholar]
- 18.Harper D, Maynard Smith J: Animal Signals. Oxford University Press,2003;176 Reference Source [Google Scholar]
- 19.Zahavi A: Mate selection-a selection for a handicap. J Theor Biol. 1975;53(1):205–214. 10.1016/0022-5193(75)90111-3 [DOI] [PubMed] [Google Scholar]
- 20.Zahavi A, Zahavi A: The Handicap Principle: A missing piece of Darwin’s puzzle. Oxford University Press,1997. Reference Source [Google Scholar]
- 21.Ugrumov MV, Saifetyarova JY, Lavrentieva AV, et al. : Developing brain as an endocrine organ: secretion of dopamine. Mol Cell Endocrinol. 2012;348(1):78–86. 10.1016/j.mce.2011.07.038 [DOI] [PubMed] [Google Scholar]
- 22.Saifetyarova YY, Melnikova VI, Sapronova AY, et al. : The developing brain as an endocrine source of norepinephrine in the blood. Dokl Biol Sci. 2014;454:5–8. 10.1134/S0012496614010116 [DOI] [PubMed] [Google Scholar]
- 23.Agnati LF, Guidolin D, Guescini M, et al. : Understanding wiring and volume transmission. Brain Res Rev. 2010;64(1):137–159. 10.1016/j.brainresrev.2010.03.003 [DOI] [PubMed] [Google Scholar]
- 24.Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. : Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16(3):675–686. 10.1016/S0896-6273(00)80086-0 [DOI] [PubMed] [Google Scholar]
- 25.Parsons MP, Raymond LA: Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014;82(2):279–293. 10.1016/j.neuron.2014.03.030 [DOI] [PubMed] [Google Scholar]
- 26.Schubert D, Piasecki D: Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J Neurosci. 2001;21(19):7455–7462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Barbour B, Brew H, Attwell D: Electrogenic glutamate uptake in glial cells is activated by intracellular potassium. Nature. 1988;335(6199):433–435. 10.1038/335433a0 [DOI] [PubMed] [Google Scholar]
- 28.Rossi DJ, Oshima T, Attwell D: Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature. 2000;403(6767):316–321. 10.1038/35002090 [DOI] [PubMed] [Google Scholar]
- 29.Campos F, Sobrino T, Ramos-Cabrer P, et al. : Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab. 2011;31(6):1378–1386. 10.1038/jcbfm.2011.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Sheldon AL, Robinson MB: The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51(6–7):333–355. 10.1016/j.neuint.2007.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Waagepetersen HS, Qu H, Sonnewald U, et al. : Role of glutamine and neuronal glutamate uptake in glutamate homeostasis and synthesis during vesicular release in cultured glutamatergic neurons. Neurochem Int. 2005;47(1–2):92–102. 10.1016/j.neuint.2005.04.012 [DOI] [PubMed] [Google Scholar]
- 32.Zou J, Wang YX, Dou FF, et al. : Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem Int. 2010;56(4):577–584. 10.1016/j.neuint.2009.12.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Takeda K, Ishida A, Takahashi K, et al. : Synaptic vesicles are capable of synthesizing the VGLUT substrate glutamate from α-ketoglutarate for vesicular loading. J Neurochem. 2012;121(2):184–196. 10.1111/j.1471-4159.2012.07684.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Gebicki S, Gebicki JM: Formation of peroxides in amino acids and proteins exposed to oxygen free radicals. Biochem J. 1993;289(Pt 3):743–749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Stadtman ER: Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem. 1993;62:797–821. 10.1146/annurev.bi.62.070193.004053 [DOI] [PubMed] [Google Scholar]
- 36.Zecca L, Youdim MB, Riederer P, et al. : Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863–873. 10.1038/nrn1537 [DOI] [PubMed] [Google Scholar]
- 37.Smythies J: Redox mechanisms at the glutamate synapse and their significance: a review. Eur J Pharmacol. 1999;370(1):1–7. 10.1016/S0014-2999(99)00048-5 [DOI] [PubMed] [Google Scholar]
- 38.Napolitano A, Pezzella A, Prota G: New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6–hydroxydopamine and 6, 7–dihydroxytetrahydroisoquinoline. Chem Res Toxicol. 1999;12(11):1090–1097. 10.1021/tx990079p [DOI] [PubMed] [Google Scholar]
- 39.Dexter DT, Statton SA, Whitmore C, et al. : Clinically available iron chelators induce neuroprotection in the 6–OHDA model of Parkinson’s disease after peripheral administration. J Neural Transm. 2011;118(2):223–231. 10.1007/s00702-010-0531-3 [DOI] [PubMed] [Google Scholar]
- 40.Dantzer R, O’Connor JC, Lawson MA, et al. : Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426–436. 10.1016/j.psyneuen.2010.09.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Wichers MC, Koek GH, Robaeys G, et al. : IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538–544. 10.1038/sj.mp.4001600 [DOI] [PubMed] [Google Scholar]
- 42.Jones CE, Underwood CK, Coulson EJ, et al. : Copper induced oxidation of serotonin: analysis of products and toxicity. J Neurochem. 2007;102(4):1035–1043. 10.1111/j.1471-4159.2007.04602.x [DOI] [PubMed] [Google Scholar]
- 43.Hadi N, Singh S, Ahmad A, et al. : Strand scission in DNA induced by 5-hydroxytryptamine (serotonin) in the presence of copper ions. Neurosci Lett. 2001;308(2):83–86. 10.1016/S0304-3940(01)01993-0 [DOI] [PubMed] [Google Scholar]
- 44.Jiang XR, Wrona MZ, Dryhurst G: Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: possible implications in neurodegenerative brain disorders. Chem Res Toxicol. 1999;12(5):429–436. 10.1021/tx9801615 [DOI] [PubMed] [Google Scholar]
- 45.Peters GH, Wang C, Cruys-Bagger N, et al. : Binding of serotonin to lipid membranes. J Amer Chem Soc. 2013;135(6):2164–71. 10.1021/ja306681d [DOI] [PubMed] [Google Scholar]
- 46.Milutinovic PS, Yang L, Cantor RS, et al. : Anesthetic-like modulation of a gamma-aminobutyric acid type A, trychnine-sensitive glycine, and N-methyl-d-aspartate receptors by coreleased neurotransmitters. Anesth Analg. 2007;105(2):386–92. 10.1213/01.ane.0000267258.17197.7d [DOI] [PubMed] [Google Scholar]
- 47.Drewes LR, Singh AK: Choline transport and metabolism in soman- or sarin-intoxicated brain. J Neurochem. 1988;50(3):868–875. 10.1111/j.1471-4159.1988.tb02993.x [DOI] [PubMed] [Google Scholar]
- 48.Pope CN: Organophosphorus pesticides: do they all have the same mechanism of toxicity? J Toxicol Environ Health B Crit Rev. 1999;2(2):161–181. 10.1080/109374099281205 [DOI] [PubMed] [Google Scholar]
- 49.Doležal V, Tuček S: Activation of muscarinic receptors stimulates the release of choline from brain slices. Biochem Biophys Res Commun. 1984;120(3):1002–1007. 10.1016/S0006-291X(84)80206-5 [DOI] [PubMed] [Google Scholar]
- 50.Martin SE, de Fiebre NE, de Fiebre CM: The alpha7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against beta-amyloid1-42 toxicity in primary neuron-enriched cultures. Brain Res. 2004;1022(1–2):254–256. 10.1016/j.brainres.2004.07.016 [DOI] [PubMed] [Google Scholar]
- 51.Ranck JL, Tocanne JF: Choline and acetylcholine induce interdigitation of hydrocarbon chains in dipalmitoylphosphatidylglycerol lamellar phase with stiff chains. FEBS Lett. 1982;143(2):171–174. 10.1016/0014-5793(82)80092-6 [DOI] [PubMed] [Google Scholar]
- 52.Kantor DB, Kolodkin AL: Curbing the excesses of youth: molecular insights into axonal pruning. Neuron. 2003;38(6):849–852. 10.1016/S0896-6273(03)00364-7 [DOI] [PubMed] [Google Scholar]
- 53.Vanderhaeghen P, Cheng HJ: Guidance molecules in axon pruning and cell death. Cold Spring Harb Perspect Biol. 2010;2(6):a001859. 10.1101/cshperspect.a001859 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Stettler DD, Yamahachi H, Li W, et al. : Axons and synaptic boutons are highly dynamic in adult visual cortex. Neuron. 2006;49(6):877–887. 10.1016/j.neuron.2006.02.018 [DOI] [PubMed] [Google Scholar]
- 55.Zito K, Svoboda K: Activity-dependent synaptogenesis in the adult Mammalian cortex. Neuron. 2002;35(6):1015–1017. 10.1016/S0896-6273(02)00903-0 [DOI] [PubMed] [Google Scholar]
- 56.Goodman CS, Shatz CJ: Developmental mechanisms that generate precise patterns of neuronal connectivity. Cell. 1993;72(Suppl):77–98. 10.1016/S0092-8674(05)80030-3 [DOI] [PubMed] [Google Scholar]
- 57.Noh J, Seal RP, Garver JA, et al. : Glutamate co-release at GABA/glycinergic synapses is crucial for the refinement of an inhibitory map. Nat Neurosci. 2010;13(2):232–238. 10.1038/nn.2478 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Boulland JL, Qureshi T, Seal RP, et al. : Expression of the vesicular glutamate transporters during development indicates the widespread corelease of multiple neurotransmitters. J Comp Neurol. 2004;480(3):264–280. 10.1002/cne.20354 [DOI] [PubMed] [Google Scholar]
- 59.Sinakevitch I, Grau Y, Strausfeld NJ, et al. : Dynamics of glutamatergic signaling in the mushroom body of young adult Drosophila. Neural Dev. 2010;5:10. 10.1186/1749-8104-5-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Cellot G, Cherubini E: Functional role of ambient GABA in refining neuronal circuits early in postnatal development. Front Neural Circuits. 2013;7:136. 10.3389/fncir.2013.00136 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Adell A, Celada P, Abellán MT, et al. : Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev. 2002;39(2–3):154–180. 10.1016/S0165-0173(02)00182-0 [DOI] [PubMed] [Google Scholar]
- 62.O’Brien BJ, Isayama T, Richardson R, et al. : Intrinsic physiological properties of cat retinal ganglion cells. J Physiol. 2002;538(Pt 3):787–802. 10.1113/jphysiol.2001.013009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Barres BA, Silverstein BE, Corey DP, et al. : Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron. 1988;1(9):791–803. 10.1016/0896-6273(88)90127-4 [DOI] [PubMed] [Google Scholar]
- 64.Usherwood PN, Machili P, Leaf G: L-Glutamate at insect excitatory nerve-muscle synapses. Nature. 1968;219(5159):1169–1172. 10.1038/2191169a0 [DOI] [PubMed] [Google Scholar]
- 65.Jan LY, Jan YN: L-glutamate as an excitatory transmitter at the Drosophila larval neuromuscular junction. J Physiol. 1976;262(1):215–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Abbott NJ, Patabendige AA, Dolman DE, et al. : Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25. 10.1016/j.nbd.2009.07.030 [DOI] [PubMed] [Google Scholar]
- 67.Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53. 10.1038/nrn1824 [DOI] [PubMed] [Google Scholar]
- 68.Santiago M, Cano J, Reinoso-Suárez F, et al. : Age-related changes of serotonin and its metabolites content in the visual system of the rat. Mech Ageing Dev. 1987;38(2):157–165. 10.1016/0047-6374(87)90075-3 [DOI] [PubMed] [Google Scholar]
- 69.Godefroy F, Bassant MH, Lamour Y, et al. : Effect of aging on dopamine metabolism in the rat cerebral cortex: a regional analysis. J Neural Transm Gen Sect. 1991;83(1–2):13–24. 10.1007/BF01244448 [DOI] [PubMed] [Google Scholar]
- 70.Hussain AM, Mitra AK: Effect of aging on tryptophan hydroxylase in rat brain: implications on serotonin level. Drug Metab Dispos. 2000;28(9):1038–1042. [PubMed] [Google Scholar]
- 71.Hädel S, Wirth C, Rapp M, et al. : Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging. 2013;38(6):1480–1487. 10.1002/jmri.24123 [DOI] [PubMed] [Google Scholar]
- 72.De La Cruz CP, Revilla E, Venero JL, et al. : Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat. Free Radical Bio Med. 1996;20(1):53–61. 10.1016/0891-5849(95)02025-X [DOI] [PubMed] [Google Scholar]
- 73.Borges CR, Geddes T, Watson JT, et al. : Dopamine biosynthesis is regulated by S-glutathionylation. Potential mechanism of tyrosine hydroxylase inhibition during oxidative stress. J Biol Chem. 2002;277(50):48295–48302. 10.1074/jbc.M209042200 [DOI] [PubMed] [Google Scholar]
- 74.Obeso JA, Olanow CW, Nutt JG: Levodopa motor complications in Parkinson’s disease. Trends Neurosci. 2000;23(10 Suppl):S2–S7. 10.1016/S1471-1931(00)00031-8 [DOI] [PubMed] [Google Scholar]
- 75.Tsunemi A, Utsuyama M, Seidler BK, et al. : Age-related decline of brain monoamines in mice is reversed to young level by Japanese herbal medicine. Neurochem Res. 2005;30(1):75–81. 10.1007/s11064-004-9688-1 [DOI] [PubMed] [Google Scholar]
- 76.Le-Corronc H, Rigo JM, Branchereau P, et al. : GABA(A) receptor and glycine receptor activation by paracrine/autocrine release of endogenous agonists: more than a simple communication pathway. Mol Neurobiol. 2011;44(1):28–52. 10.1007/s12035-011-8185-1 [DOI] [PubMed] [Google Scholar]
- 77.Balaban RS, Nemoto S, Finkel T: Mitochondria, oxidants, and aging. Cell. 2005;120(4):483–495. 10.1016/j.cell.2005.02.001 [DOI] [PubMed] [Google Scholar]
- 78.Falk-Vairant J, Israel M, Bruner J, et al. : Enhancement of quantal transmitter release and mediatophore expression by cyclic AMP in fibroblasts loaded with acetylcholine. Neuroscience. 1996;75(2):353–360. 10.1016/0306-4522(96)00260-6 [DOI] [PubMed] [Google Scholar]
- 79.Berridge MJ, Bootman MD, Roderick HL: Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–529. 10.1038/nrm1155 [DOI] [PubMed] [Google Scholar]
- 80.Soreq H, Seidman S: Acetylcholinesterase--new roles for an old actor. Nat Rev Neurosci. 2001;2(4):294–302. 10.1038/35067589 [DOI] [PubMed] [Google Scholar]
- 81.Azcón-Bieto J, Osmond CB: Relationship between Photosynthesis and Respiration: The Effect of Carbohydrate Status on the Rate of CO(2) Production by Respiration in Darkened and Illuminated Wheat Leaves. Plant Physiol. 1983;71(3):574–581. 10.1104/pp.71.3.574 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Genever PG, Skerry TM: Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J. 2001;15(9):1586–1588. 10.1096/fj.00-0594fje [DOI] [PubMed] [Google Scholar]
- 83.Wessler I, Kirkpatrick CJ, Racké K: Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther. 1998;77(1):59–79. 10.1016/S0163-7258(97)00085-5 [DOI] [PubMed] [Google Scholar]
- 84.Hinoi E, Takarada T, Ueshima T, et al. : Glutamate signaling in peripheral tissues. Eur J Biochem. 2004;271(1):1–13. 10.1046/j.1432-1033.2003.03907.x [DOI] [PubMed] [Google Scholar]
- 85.Harris KD, Zahavi A: The evolution of ACh and GABA as neurotransmitters: a hypothesis. Med Hypotheses. 2013;81(5):760–762. 10.1016/j.mehy.2013.07.045 [DOI] [PubMed] [Google Scholar]
- 86.Tuček S: The synthesis of acetylcholine in skeletal muscles of the rat. J Physiol. 1982;322:53–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Duguid IC, Smart TG: Retrograde activation of presynaptic NMDA receptors enhances GABA release at cerebellar interneuron-Purkinje cell synapses. Nat Neurosci. 2004;7(5):525–533. 10.1038/nn1227 [DOI] [PubMed] [Google Scholar]
